Leaderboards/Liver Diseases and Immunity

Liver Diseases and Immunity

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Jiawei Guo
Southern University of Science and Technology
2
Romée J.A.L.M. Snijders
Radboud University Nijmegen
3
Yuzo Koda
Keio University
4
Jiawen Dong
Churchill Hospital
5
Ainhoa Lapitz
University of the Basque Country
6
Carla Fiorella Murillo Perez
University Health Network
7
Laura Cristoferi
University of Milano-Bicocca
8
Pierre‐Antoine Soret
Inserm
9
Aiva Lundberg Båve
Karolinska University Hospital
10
Dawei Ding
National Clinical Research Center for Digestive Diseases

Papers

1
Publication in Endocrine Reviews (2025) [33 citations, W4411340484]
Endocrine Reviews|2025
33 cit.
2
Publication in Hepatology (2024) [13 citations, W4392452736]
Hepatology|2024
13 cit.
3
Health-related quality of life is impaired in people with autoimmune hepatitis: Results of a multicentre cross-sectional study within the European Reference Network
Hepatology|2025
13 cit.
4
Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment
Hepatology International|2024
6 cit.
5
Publication in The Lancet Diabetes & Endocrinology (2026) [3 citations, W7125582660]
The Lancet Diabetes & Endocrinology|2026
3 cit.
6
Publication in The Lancet Diabetes & Endocrinology (2024) [2 citations, W4403350523]
The Lancet Diabetes & Endocrinology|2024
2 cit.
7
Publication in Liver International (2025) [2 citations, W4414563337]
Liver International|2025
2 cit.
8
WED-158-YI Disease experience and care expectations in european patients with immune-mediated liver disease
Journal of Hepatology|2024
1 cit.
9
Publication in Journal of Hepatology (2024) [1 citation, W4399561088]
Journal of Hepatology|2024
1 cit.
10
Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?
Hepatology International|2025
1 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
David N. Assis
Yale University
2
Sonya A. MacParland
University Health Network
3
Junhao Hu
Northeast Petroleum University
4
Aliya Gulamhusein
Toronto General Hospital
5
Su‐Hyung Park
Korea Advanced Institute of Science and Technology
6
Anne Negård
University of Oslo
7
Palak Trivedi
University Hospitals Birmingham NHS Foundation Trust
8
Xiao Chen
XinHua Hospital
9
Mathilde M. Almekinders
The Netherlands Cancer Institute
10
Suzanne Wilhelmus
Leiden University Medical Center

Papers

1
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Hepatology|2022
370 cit.
2
Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver
Journal of Hepatology|2024
159 cit.
3
Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts
Gastroenterology|2024
77 cit.
4
UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis
Clinical Gastroenterology and Hepatology|2022
39 cit.
5
A virtual memory CD8+ T cell-originated subset causes alopecia areata through innate-like cytotoxicity
Nature Immunology|2023
39 cit.
6
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures
Journal of Crohn s and Colitis|2024
30 cit.
7
Reliability of preoperative MRI findings in patients with lumbar spinal stenosis
BMC Musculoskeletal Disorders|2022
25 cit.
8
Activating NO–sGC crosstalk in the mouse vascular niche promotes vascular integrity and mitigates acute lung injury
The Journal of Experimental Medicine|2022
25 cit.
9
Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis
JHEP Reports|2023
23 cit.
10
Low levels of cadmium exposure affect bone by inhibiting Lgr4 expression in osteoblasts and osteoclasts
Journal of Trace Elements in Medicine and Biology|2022
21 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Keith D. Lindor
Mayo Clinic
2
M. Eric Gershwin
University of California, Davis
3
Roger Williams
MRC Laboratory of Molecular Biology
4
Ansgar W. Lohse
Universität Hamburg
5
Diego Vergani
King's College - North Carolina
6
Christoph Schramm
European Association for the Study of Diabetes
7
Nicholas F. LaRusso
Mayo Clinic
8
Mikio Zeniya
International University of Health and Welfare
9
Yasuni Nakanuma
Fukui-ken Saiseikai Hospital
10
Oliver James
Institute for Basic Science

Papers

1
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
Journal of Hepatology|1999
2.9k cit.
2
Simplified criteria for the diagnosis of autoimmune hepatitis†
Hepatology|2008
1.9k cit.
3
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Hepatology|1999
1.6k cit.
4
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Journal of Hepatology|2017
1.5k cit.
5
Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine
Molecular Cell|2000
1.2k cit.
6
Primary Biliary Cirrhosis
New England Journal of Medicine|2005
1.2k cit.
7
Primary biliary cirrhosis # †
Hepatology|2009
1.1k cit.
8
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Hepatology|2018
883 cit.
9
Pathogenesis and natural history of osteonecrosis
Seminars in Arthritis and Rheumatism|2002
786 cit.
10
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
Hepatology|2004
729 cit.

Reagents for Liver Diseases and Immunity

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Agilent/Dako

Monoclonal Mouse Anti Human Smooth Muscle Actin

#M0851
View Evidence →
Cell Signaling TechnologyEvidence 71

COL1A1 (E8F4L) Rabbit Monoclonal Antibody

#72026$180,996
View Evidence →
Cell Signaling TechnologyEvidence 69

IL-1 beta (D3H1Z) Rabbit Monoclonal Antibody

#12507$161,351
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

UPF1 Antibody

Cited in 5 papers
#9435$317
View Evidence →
Cell Signaling TechnologyEvidence 63

Phospho-GSK-3 alpha/beta (Ser21/9) (37F11) Rabbit Monoclonal Antibody

Cited in 5 papers
#9327$179,968
View Evidence →
Cell Signaling TechnologyEvidence 67

Ki-67 (D3B5) Rabbit Monoclonal Antibody (Alexa Fluor® 555 Conjugate)

Cited in 5 papers
#20701$465
View Evidence →